Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase‐4 inhibitor on hepatic fibrosis
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase‐4 inhibitor on hepatic fibrosis
Authors
Keywords
-
Journal
HEPATOLOGY RESEARCH
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-06-09
DOI
10.1111/hepr.13385
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis
- (2018) Toshihiro Goto et al. Scientific Reports
- Relationship Between Three Commonly Used Non-invasive Fibrosis Biomarkers and Improvement in Fibrosis Stage in Patients With NASH
- (2018) Naga Chalasani et al. LIVER INTERNATIONAL
- Combining probiotics and an angiotensin‐II type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non‐alcoholic steatohepatitis
- (2018) Yasuhiko Sawada et al. HEPATOLOGY RESEARCH
- Dahuang Zexie Decoction Protects against High-Fat Diet-Induced NAFLD by Modulating Gut Microbiota-Mediated Toll-Like Receptor 4 Signaling Activation and Loss of Intestinal Barrier
- (2017) Jing Fang et al. Evidence-based Complementary and Alternative Medicine
- Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis
- (2017) Parambir S. Dulai et al. HEPATOLOGY
- Ezetimibe for the treatment of non-alcoholic fatty liver disease: A meta-analysis
- (2017) Yukiomi Nakade et al. HEPATOLOGY RESEARCH
- Pathological Findings of NASH and NAFLD
- (2017) et al. HEPATOLOGY RESEARCH
- Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis
- (2017) Yasushi Okura et al. HEPATOLOGY RESEARCH
- Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus
- (2017) Yoshio Sumida et al. HEPATOLOGY RESEARCH
- Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial
- (2017) Tisha R Joy et al. WORLD JOURNAL OF GASTROENTEROLOGY
- The pro-fibrotic role of dipeptidyl peptidase 4 in carbon tetrachloride-induced experimental liver injury
- (2016) Xin M Wang et al. IMMUNOLOGY AND CELL BIOLOGY
- Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats
- (2016) María Úbeda et al. JOURNAL OF HEPATOLOGY
- Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial
- (2016) Jeffrey Cui et al. JOURNAL OF HEPATOLOGY
- FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis
- (2016) Len Verbeke et al. Scientific Reports
- The FXR Agonist Obeticholic Acid Prevents Gut Barrier Dysfunction and Bacterial Translocation in Cholestatic Rats
- (2015) Len Verbeke et al. AMERICAN JOURNAL OF PATHOLOGY
- Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up
- (2015) Mattias Ekstedt et al. HEPATOLOGY
- Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis
- (2015) Tadashi Namisaki et al. JOURNAL OF GASTROENTEROLOGY
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Stimulation of intestinal growth and function with DPP4 inhibition in a mouse short bowel syndrome model
- (2014) Ryo Sueyoshi et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Dipeptidyl peptidase-IV inhibition prevents blood–retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats
- (2014) Andreia Gonçalves et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model
- (2014) AKITOSHI DOUHARA et al. Molecular Medicine Reports
- Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
- (2013) Sunder Mudaliar et al. GASTROENTEROLOGY
- Direct renin inhibitor, aliskiren, attenuates the progression of non-alcoholic steatohepatitis in the rat model
- (2013) Yosuke Aihara et al. HEPATOLOGY RESEARCH
- Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats
- (2013) Kosuke Kaji et al. JOURNAL OF GASTROENTEROLOGY
- Dual blockade of angiotensin-II and aldosterone suppresses the progression of a non-diabetic rat model of steatohepatitis
- (2012) Ryuichi Noguchi et al. HEPATOLOGY RESEARCH
- Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut
- (2011) Ekihiro Seki et al. JOURNAL OF PHYSIOLOGY-LONDON
- Histopathological, Immunohistochemical and Ultrastructural Studies of a Renal Mesenchymal Tumor in a Young Beagle Dog
- (2011) Yui SUZUKI et al. JOURNAL OF VETERINARY MEDICAL SCIENCE
- Farnesoid X Receptor Critically Determines the Fibrotic Response in Mice but Is Expressed to a Low Extent in Human Hepatic Stellate Cells and Periductal Myofibroblasts
- (2009) Peter Fickert et al. AMERICAN JOURNAL OF PATHOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now